Gálvez-Sánchez, R.; Salmón González, Z.; Fernández-GarcÃa, M.; Cerveró Varona, A.; González-Mesones, B.; López-Hoyos, M.; MartÃnez-Taboada, V.; Luis Hernández, J.
Impact of the 2023 ACR/EULAR Antiphospholipid Syndrome Criteria on Retinal Vein Occlusion Patients. J. Clin. Med. 2025, 14, 2826.
https://doi.org/10.3390/jcm14082826
AMA Style
Gálvez-Sánchez R, Salmón González Z, Fernández-GarcÃa M, Cerveró Varona A, González-Mesones B, López-Hoyos M, MartÃnez-Taboada V, Luis Hernández J.
Impact of the 2023 ACR/EULAR Antiphospholipid Syndrome Criteria on Retinal Vein Occlusion Patients. Journal of Clinical Medicine. 2025; 14(8):2826.
https://doi.org/10.3390/jcm14082826
Chicago/Turabian Style
Gálvez-Sánchez, Rafael, Zaida Salmón González, Magdalena Fernández-GarcÃa, Andrea Cerveró Varona, Belén González-Mesones, Marcos López-Hoyos, VÃctor MartÃnez-Taboada, and José Luis Hernández.
2025. "Impact of the 2023 ACR/EULAR Antiphospholipid Syndrome Criteria on Retinal Vein Occlusion Patients" Journal of Clinical Medicine 14, no. 8: 2826.
https://doi.org/10.3390/jcm14082826
APA Style
Gálvez-Sánchez, R., Salmón González, Z., Fernández-GarcÃa, M., Cerveró Varona, A., González-Mesones, B., López-Hoyos, M., MartÃnez-Taboada, V., & Luis Hernández, J.
(2025). Impact of the 2023 ACR/EULAR Antiphospholipid Syndrome Criteria on Retinal Vein Occlusion Patients. Journal of Clinical Medicine, 14(8), 2826.
https://doi.org/10.3390/jcm14082826